A prospective, randomized, double blind, single dose, placebo-controlled study to evaluate pharmacokinetics, safety and tolerability of ZYBK2 in healthy adult human volunteers
Latest Information Update: 27 Nov 2020
At a glance
Most Recent Events
- 04 Nov 2020 Status changed from planning to recruiting.
- 06 Mar 2020 New trial record
- 03 Mar 2020 According to a Zydus Cadila media release, the company has received an approval from the Drug Controller General of India (DCGI) to initiate this phase I trial.